Patterns of company misconduct, recidivism, and complaint resolution delays
A temporal analysis of UK pharmaceutical industry self‐regulation within the European context
Datos Bibliográficos
| ID | 7997752 |
|---|---|
| Autores | Shai Mulinari (0000-0001-8773-9796, autor de correspondencia), Dylan Pashley, Piotr Ozieranski (0000-0002-2023-3288) |
| Año | 2024 |
| Volumen | 19 |
| Número | 1 |
| Páginas | 200-217 |
| Fecha de publicación | 2024-06-20 |
| Peer Reviewed | Sí |
| Open Access | Sí |
| Tipo | ARTICLE |
| Revista | Regulation & Governance (JOURNAL) |
| Identificadores de la revista | ISSN: 1748-5983 • E-ISSN: 1748-5991 |
| Editorial | Wiley (PUBLISHER • GB) |
| DOI | 10.1111/rego.12609 |
| OpenAlex | W4399862717 |
| Idioma | EN |
| Citas recibidas | 2 |
| Referencias citadas | 57 |
Interfirm self‐regulation through trade associations is common but its effectiveness is debated and likely varies by time, country, and industry. This study examines self‐regulation of pharmaceutical marketing, characterized by delegation of major regulatory responsibilities to trade associations' self‐regulatory bodies. In addressing critical research gaps, this study first analyzes 1,776 complaints against pharmaceutical companies in the UK over 18 years (2004–2021). Findings regarding severe, repeat, and complex offending, and delays in complaint resolution raise significant concerns about the adequacy of UK's self‐regulation in deterring wrongdoing. Second, the study conducts international comparisons using recent complaints data from 30 European pharmaceutical industry self‐regulatory bodies. Despite shortcomings of UK's self‐regulation, it appears more adept at identifying potential breaches compared to most other countries, suggesting significant underdetection or underreporting of drug company misconduct in Europe. On balance, our findings are concerning given the negative effects of poorly regulated pharmaceutical marketing on medical practice and health
Business · Complaint · Context (archaeology · Criminology · Misconduct · Pharmaceutical industry · Political science · Recidivism · Law · Medicine · Pharmaceutical Economics and Policy · Pharmaceutical industry and healthcare · Psychology · Regulation and Compliance Studies · Accounting · Pharmacology
Varieties of Private Market Regulation
Responsive Regulation
The Open Corporation
Industry Self-Regulation Without Sanctions
Enforced Self-Regulation
Pharmaceutical industry self-regulation and non-transparency
A comparative analysis of risk management strategies in European Union and United States pharmaceutical regulation
International comparison of pharmaceutical industry payment disclosures in the UK and Japan
Regulating the Activities of Oil Multinationals in Nigeria
Regulating Pharmaceutical Industry Marketing
The will of Congress? Permissive regulation and the strategic use of labeling for the anti-influenza drug Relenza
The Interplay of Public Health Law and Industry Self-Regulation
The Food Industry and Self-Regulation
Self‐regulation Within the Regulatory State
Transnational Regulation of the Pharmaceutical Industry
Regulating drug information in Europe
Complaining about rivals
Transcending the deregulation debate? Regulation, risk, and the enforcement of health and safety law in theUK
Industry Self‐Regulation
| Obras citantes distintas | 2 |
|---|---|
| Citas por año | 2 |
| Intervalo de citas | 2025 - 2026 (2) |
| Velocidad de citación | current |
| Altamente citado | No |
| Tipos de cita | Neutras: 2 |